EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies

Viktoria Eleftheriadou, Emma Rush, Lorraine Jacques

Clinical and Experimental Dermatology · 2025

DOI: 10.1093/ced/llaf249 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Viktoria Eleftheriadou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, UK. Hauptthemen laut MEDLINE: Vitiligo, Registries, Phototherapy, Immunomodulating Agents. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vitiligo is the most common depigmentation disorder, affecting around 1% of the population worldwide. Currently, no national or international registry for patients with vitiligo exists. Individual dermatologists maintain descriptive databases of such patients, which involve patients in one centre. However, such single-centre registries do not aim to establish the short- and long-term safety (pharmacovigilance) and effectiveness of vitiligo therapies. As an initial step for the development of a national UK registry for patients with vitiligo, development of a pilot multicentre registry in the UK is needed. This pilot study is being developed in collaboration with the British Association of Dermatologists. VIRTUAL-UK (VItiligo RegisTry for adUlts And chiLdren) assesses treatment effectiveness and safety as well as treatment impact on quality of life. The registry includes children and adults with vitiligo who receive phototherapy or novel topical and/or systemic immunomodulatory therapies. The VIRTUAL-UK registry will ultimately (i) inform treatment guidelines, (ii) provide pharmacogenetic and pharmacodynamic research data, (iii) help answer questions on skin cancer risk for patients with vitiligo who receive prolonged phototherapy courses, especially regarding high cumulative exposures in children with less deeply pigmented skin, and (iv) help to identify those patients likely to experience rapid disease progression. As a result, this registry will ultimately improve and personalize patient care. With novel topical and oral immunomodulatory therapies having just entered vitiligo clinical practice, the timing is ideal to harness the high-quality data collection offered by the UK National Health Service.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoRegistriesPhototherapyImmunomodulating AgentsHumansChildAdultProspective StudiesUnited KingdomPilot ProjectsAdolescentMaleFemaleYoung Adult

Substanzen

Immunomodulating Agents

Autor:innen und Institutionen

  • Dermatology, Royal Wolverhampton NHS Trust, Wolverhampton, UK.
  • Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
  • Vitiligo Support UK, London, UK.
  • Research and Development Directorate, Royal Wolverhampton NHS Trust, Wolverhampton, UK.

Zitieren

APA

Eleftheriadou, V., Rush, E., & Jacques, L. (2025). Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf249

Vancouver

Eleftheriadou V, Rush E, Jacques L. Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf249

BibTeX
@article{Eleftheriadou2025,
  author = {Eleftheriadou, Viktoria and Rush, Emma and Jacques, Lorraine},
  title = {Multicentre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical or systemic immunomodulatory therapies},
  journal = {Clinical and Experimental Dermatology},
  year = {2025},
  doi = {10.1093/ced/llaf249}
}
Kostenlos starten →